The variability of tumor responses to chemotherapeutic agents is a topic of major interest in current cancer research. Advances in the knowledge of dysregulation of key molecular pathways in cancer cells have enabled techniques to be developed that can profile tumor cells for their genetic background, allowing selection of anticancer agents on an individual basis. The next generation of anticancer treatments might therefore be tailored according to the molecular alterations identified in tumor cells of individual patients. However, before these alterations can be exploited from a therapeutic point of view, it is necessary to understand how such alterations influence the cellular pathways that control sensitivity to chemotherapeutic agents. Pharmacogenetics and pharmacoproteomics, novel disciplines that investigate the relationship between gene and protein expression in tumor cells and the response to anticancer agents, will be instrumental in developing optimal chemotherapeutic regimens for patients with non-Hodgkin's lymphoma.
Pharmacogenetics and proteomics of anticancer drugs in non-Hodgkin's lymphoma / L. Loni, F. de Braud, P. Zinzani, R. Danesi. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - 44:suppl. 3(2003), pp. S115-S122. ((Intervento presentato al 1. convegno International Workshop on Non-Hodgkins Lymphoma tenutosi a Chantilly nel 2002.
|Titolo:||Pharmacogenetics and proteomics of anticancer drugs in non-Hodgkin's lymphoma|
|Parole Chiave:||non-Hodgkin's lymphoma; pharmacogenetics; pharmacoproteomics; chemotherapy|
|Settore Scientifico Disciplinare:||Settore MED/06 - Oncologia Medica|
|Data di pubblicazione:||2003|
|Appare nelle tipologie:||01 - Articolo su periodico|
File in questo prodotto:
|Pharmacogenetics and Proteomics of Anticancer Drugs in Non Hodgkin s Lymphoma.pdf||Publisher's version/PDF||Administrator Richiedi una copia|